Human evidence falls short

Human studies
leave big gaps.

Look for a study in people, a fair comparison, and a result that was actually reported. Each part matters.

The human evidence is small.

FDA is short for Food and Drug Administration, the US drug agency.

In the FDA review checked on September 28, 2026, five studies included about 80 people who received BPC-157.

As of September 28, 2026, only two of those studies compared people given BPC-157 with people given a dummy treatment.

Those two studies were available only as short summaries presented at meetings, rather than detailed published reports.

How small the published reports were

Knee pain: 17 people in a review of care records.

Bladder pain: 12 women in a report with no comparison group.

Into a vein: 2 adults in a report with no comparison group.

Each bar shows how many people were in that report.

These reports had no comparison group, so they cannot show BPC-157 caused any reported improvement.

A tendon is the strong tissue that joins a muscle to a bone.

The findings about tendon healing come from studies in rats and do not prove that BPC-157 heals these injuries in people.

By September 28, 2026, injury studies had reported no results from a comparison of dummy treatment and BPC-157.

Ask whether a claim is about people with the same problem, what they were compared with, and how improvement was measured.

ClinicalTrials.gov is the US government’s list of study records. A record can describe a planned study before it has any results.

On September 28, 2026, a study in China was looking for people with strained hamstrings, the muscles along the back of the thigh.

On that date, a US study of BPC-157 after shoulder surgery had not begun.

Neither study had reported results as of September 28, 2026.